Showing results (231-240 of 238) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 238 results.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition|January 15, 2026
[Prevalence and Influencing Factors of Functional Gastrointestinal Disorders Among Infants Aged 0 to 9 Months With Gastrointestinal Discomfort in China: A Multicenter Cross-Sectional Survey]Zhiling Wang, Xintong Jia, Chijun Hu, et al.
JAMA Pediatrics|November 17, 2025
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical TrialRavi Savarirayan, Ciara McDonnell, Carlos A Bacino, et al.
Autism : the International Journal of Research and Practice|April 13, 2021
Psychometric properties of the Chinese Parent Version of the Autism Spectrum Rating Scale: Rasch analysisWeili Yan, Richard J Siegert, Hao Zhou, et al.
The Journal of Clinical Endocrinology and Metabolism|April 16, 2022
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year ResultsAristides K Maniatis, Samuel J Casella, Ulhas M Nadgir, et al.
Neuroscience Bulletin|July 2, 2020
Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 YearsHao Zhou, Xiu Xu, Weili Yan, et al.
Eclinicalmedicine|October 12, 2023
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trialRavi Savarirayan, Daniel G Hoernschemeyer, Merete Ljungberg, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Pageof 24